• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一项纵向队列研究中,14%的四价疫苗接种者体内未检测到HPV18抗体。

Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study.

作者信息

Gray Penelope, Mariz Filipe Colaço, Eklund Carina, Eriksson Tiina, Faust Helena, Kann Hanna, Müller Martin, Paavonen Jorma, Pimenoff Ville N, Sehr Peter, Surcel Heljä-Marja, Dillner Joakim, Waterboer Tim, Lehtinen Matti

机构信息

Center for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

Tumorvirus-Specific Vaccination Strategies, Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany.

出版信息

NPJ Vaccines. 2024 Aug 13;9(1):146. doi: 10.1038/s41541-024-00941-w.

DOI:10.1038/s41541-024-00941-w
PMID:39138224
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11322158/
Abstract

Although HPV vaccines are highly efficacious, a notable proportion of quadrivalent vaccinees are HPV18 seronegative post-vaccination. We have investigated this findings' validity by comparing vaccine-induced antibody responses using two different immunoassays. 6558 16-17-year-old females participated in the FUTURE II (NCT00092534) and PATRICIA (NCT00122681) trials in 2002-2004. Both the quadrivalent and bivalent vaccine recipients (QVR and BVR) received three doses. Twelve-year follow-up for 648 vaccinees was conducted by the Finnish Maternity Cohort. The presence of neutralising and binding HPV antibodies was analysed via HPV pseudovirion-based neutralisation and pseudovirion-binding assays. Four percent and 14.3% of the QVRs were seronegative for neutralising and binding antibodies to HPV16 and HPV18, respectively. No BVRs were HPV16/18 seronegative post-vaccination. The antibody titres were strongly correlated between the assays, Pearson's correlation coefficient, r = 0.92 and 0.85, and r = 0.91 and 0.86 among the QVRs and BVRs respectively. Fourteen percent of QVRs lacked detectable HPV18 antibodies in long-term follow-up.

摘要

尽管人乳头瘤病毒(HPV)疫苗具有很高的效力,但相当一部分接种四价疫苗的人在接种后对HPV18呈血清阴性。我们通过使用两种不同的免疫测定法比较疫苗诱导的抗体反应,来研究这一结果的有效性。2002年至2004年,6558名16 - 17岁的女性参与了FUTURE II(NCT00092534)和PATRICIA(NCT00122681)试验。四价疫苗和二价疫苗的接种者(QVR和BVR)均接种了三剂。芬兰孕产妇队列对648名接种者进行了12年的随访。通过基于HPV假病毒的中和试验和假病毒结合试验分析了中和性和结合性HPV抗体的存在情况。QVR中分别有4%和14.3%的人对HPV16和HPV18的中和抗体和结合抗体呈血清阴性。接种疫苗后,没有BVR对HPV16/18呈血清阴性。两种测定法之间的抗体滴度高度相关,QVR和BVR中的Pearson相关系数分别为r = 0.92和0.85,以及r = 0.91和0.86。在长期随访中,14%的QVR检测不到HPV18抗体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/11322158/57ad6caddb1d/41541_2024_941_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/11322158/f90fb4866272/41541_2024_941_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/11322158/809c38229f3e/41541_2024_941_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/11322158/57ad6caddb1d/41541_2024_941_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/11322158/f90fb4866272/41541_2024_941_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/11322158/809c38229f3e/41541_2024_941_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c3/11322158/57ad6caddb1d/41541_2024_941_Fig3_HTML.jpg

相似文献

1
Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study.在一项纵向队列研究中,14%的四价疫苗接种者体内未检测到HPV18抗体。
NPJ Vaccines. 2024 Aug 13;9(1):146. doi: 10.1038/s41541-024-00941-w.
2
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.二价或四价 HPV 疫苗诱导的中和抗体的持久性及其与疗效的相关性:两项随机、双盲、多中心、III 期临床试验数据的联合随访分析。
Lancet Infect Dis. 2021 Oct;21(10):1458-1468. doi: 10.1016/S1473-3099(20)30873-2. Epub 2021 May 31.
3
Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.在有组织的疫苗接种计划目标人群中,二价和四价人乳头瘤病毒疫苗诱导产生的中和及交叉中和抗体滴度
Vaccine. 2014 Sep 15;32(41):5357-62. doi: 10.1016/j.vaccine.2014.07.014. Epub 2014 Jul 18.
4
Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort.人类乳头瘤病毒疫苗接种后的持续交叉反应性抗体应答:芬兰母婴队列的长达 12 年随访。
J Infect Dis. 2021 Jun 4;223(11):1992-2000. doi: 10.1093/infdis/jiaa617.
5
Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.用于检测人乳头瘤病毒16型和18型的多重竞争性Luminex免疫测定、多重IgG Luminex免疫测定和基于假病毒的中和测定之间的一致性评估。
Vaccine. 2014 Oct 7;32(44):5880-7. doi: 10.1016/j.vaccine.2014.08.004. Epub 2014 Aug 19.
6
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.不同人乳头瘤病毒(HPV)疫苗类型及接种程序对预防女性和男性HPV相关疾病的比较。
Cochrane Database Syst Rev. 2019 Nov 22;2019(11):CD013479. doi: 10.1002/14651858.CD013479.
7
Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.接种卉妍康®或加卫苗®疫苗的12至15岁女孩针对人乳头瘤病毒16型、18型、31型和45型的体液免疫反应之间的关系
PLoS One. 2015 Oct 23;10(10):e0140926. doi: 10.1371/journal.pone.0140926. eCollection 2015.
8
Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials.在坦桑尼亚,比较 9-14 岁女孩接种一剂 HPV 疫苗(DoRIS)与肯尼亚 15-20 岁年轻女性接种一剂 HPV 疫苗(KEN SHE):一项免疫桥接分析随机对照试验。
Lancet Glob Health. 2024 Mar;12(3):e491-e499. doi: 10.1016/S2214-109X(23)00586-7.
9
Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines.二价和四价人乳头瘤病毒疫苗诱导的针对人乳头瘤病毒6/16/18/31/33/45/52/58型的中和及交叉中和抗体水平峰值。
NPJ Vaccines. 2020 Feb 14;5(1):14. doi: 10.1038/s41541-020-0165-x. eCollection 2020.
10
Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.在第21个月时评估二剂次与三剂次四价人乳头瘤病毒疫苗的免疫原性:替代接种方案的流行病学监测机制
Hum Vaccin Immunother. 2016;12(1):30-8. doi: 10.1080/21645515.2015.1058458. Epub 2015 Jul 25.

引用本文的文献

1
Scientific approaches to defining HPV vaccine-induced protective immunity.定义HPV疫苗诱导的保护性免疫的科学方法。
Int J Cancer. 2025 May 15;156(10):1848-1857. doi: 10.1002/ijc.35345. Epub 2025 Feb 13.

本文引用的文献

1
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.在印度,对 9-14 岁女孩和男孩接种新型四价 HPV 疫苗与对 15-26 岁女性接种已上市的四价 HPV 疫苗的免疫原性和安全性比较:一项随机、主动对照、多中心、2/3 期临床试验。
Lancet Oncol. 2023 Dec;24(12):1321-1333. doi: 10.1016/S1470-2045(23)00480-1. Epub 2023 Nov 7.
2
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.在中国,18-26 岁女性中,大肠杆菌生产的 9 价人乳头瘤病毒疫苗与佳达修 9 的头对头免疫原性比较:一项随机、双盲临床试验。
Lancet Infect Dis. 2023 Nov;23(11):1313-1322. doi: 10.1016/S1473-3099(23)00275-X. Epub 2023 Jul 17.
3
Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination.接种加德西(Gardasil®)和卉妍康(Cervarix®)疫苗后HPV特异性抗体Fc效应器功能的差异。
NPJ Vaccines. 2023 Mar 15;8(1):39. doi: 10.1038/s41541-023-00628-8.
4
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination.评价接种四价 HPV 疫苗 10 年后的免疫应答。
Vaccine. 2023 Jan 4;41(1):236-245. doi: 10.1016/j.vaccine.2022.11.044. Epub 2022 Nov 26.
5
Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.一剂人乳头瘤病毒疫苗与两剂或三剂在坦桑尼亚女孩中的免疫原性和安全性比较(DoRIS):一项开放标签、随机、非劣效性试验。
Lancet Glob Health. 2022 Oct;10(10):e1473-e1484. doi: 10.1016/S2214-109X(22)00309-6.
6
Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies?单剂 HPV 疫苗免疫:非中和抗体是否有作用?
Trends Immunol. 2022 Oct;43(10):815-825. doi: 10.1016/j.it.2022.07.011. Epub 2022 Aug 20.
7
Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses.双价和九价人乳头瘤病毒疫苗诱导的抗体反应的头对头比较。
J Infect Dis. 2022 Sep 28;226(7):1195-1199. doi: 10.1093/infdis/jiac190.
8
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.二价或四价 HPV 疫苗诱导的中和抗体的持久性及其与疗效的相关性:两项随机、双盲、多中心、III 期临床试验数据的联合随访分析。
Lancet Infect Dis. 2021 Oct;21(10):1458-1468. doi: 10.1016/S1473-3099(20)30873-2. Epub 2021 May 31.
9
Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort.人类乳头瘤病毒疫苗接种后的持续交叉反应性抗体应答:芬兰母婴队列的长达 12 年随访。
J Infect Dis. 2021 Jun 4;223(11):1992-2000. doi: 10.1093/infdis/jiaa617.
10
HPV Vaccination and the Risk of Invasive Cervical Cancer.HPV 疫苗接种与浸润性宫颈癌风险。
N Engl J Med. 2020 Oct 1;383(14):1340-1348. doi: 10.1056/NEJMoa1917338.